Genprex

Category: Press Releases

Genprex to Participate in a Monthly CEO Roadshow Webinar Series

Series to highlight Genprex’s novel gene therapy pipeline in cancer and diabetes

Read More

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Genprex announced that the FDA has confirmed all comments have been addressed regarding the Company’s protocol for the Acclaim-1 clinical trial

Read More

Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series

Investor presentation to highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer

Read More

Genprex to Participate in Upcoming May Investor Conferences

Investor presentations to highlight novel gene therapies for cancer and diabetes and upcoming clinical trials in non-small cell lung cancer

Read More

Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer

Amendment to existing worldwide, exclusive license agreement expands Genprex’s oncology franchise

Read More


Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Acclaim-2 Clinical Trial Combines REQORSA™ immunogene therapy with Merck & Co’s Keytruda®

Read More

Genprex to Participate in CEO Roadshow Webinar Series

Webinar series will feature a weekly company overview highlighting the Genprex’s gene therapy pipeline in cancer and diabetes

Read More

Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes

Groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells is potentially applicable to both Type 1 and Type 2 diabetes

Read More

Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting

Collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC).

Read More